Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.

Donohue MC, Gamst AC, Aisen PS.

Alzheimers Dement. 2011 Mar;7(2):245-6; author reply 247-9. doi: 10.1016/j.jalz.2010.12.013. No abstract available.

PMID:
21414558
2.

Is plasma amyloid-beta a reliable biomarker for Alzheimer's disease?

Zetterberg H.

Recent Pat CNS Drug Discov. 2008 Jun;3(2):109-11. Review.

PMID:
18537770
3.

Do CSF biomarkers help clinicians predict the progression of mild cognitive impairment to dementia?

Mitchell AJ, Monge-Argilés JA, Sánchez-Paya J.

Pract Neurol. 2010 Aug;10(4):202-7. doi: 10.1136/jnnp.2010.217778. Review.

PMID:
20647526
4.

Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design.

van Rossum IA, Vos S, Handels R, Visser PJ.

J Alzheimers Dis. 2010;20(3):881-91. doi: 10.3233/JAD-2010-091606. Review.

PMID:
20413876
5.

Biochemical markers in Alzheimer's disease clinical trials.

Zetterberg H, Mattsson N, Shaw LM, Blennow K.

Biomark Med. 2010 Feb;4(1):91-8. Review.

PMID:
20387305
7.

[Clinical aspects of Alzheimer's disease].

Namba Y.

Nihon Rinsho. 2004 Jan;62 Suppl:61-5. Review. Japanese. No abstract available.

PMID:
15011321
8.

Clinical trial methodologies for disease-modifying therapeutic approaches.

Aisen PS.

Neurobiol Aging. 2011 Dec;32 Suppl 1:S64-6. doi: 10.1016/j.neurobiolaging.2011.09.008. Epub 2011 Oct 8. Review.

9.

Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges.

Bartlett JW, Frost C, Mattsson N, Skillbäck T, Blennow K, Zetterberg H, Schott JM.

Biomark Med. 2012 Aug;6(4):391-400. doi: 10.2217/bmm.12.49. Review.

PMID:
22917141
10.

Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is 'too big to fail'.

Castellani RJ, Smith MA.

J Pathol. 2011 Jun;224(2):147-52. doi: 10.1002/path.2885. Review.

PMID:
21557219
11.

Plasma biomarkers for Alzheimer's disease: much needed but tough to find.

Bazenet C, Lovestone S.

Biomark Med. 2012 Aug;6(4):441-54. doi: 10.2217/bmm.12.48. Review.

PMID:
22917146
12.

Considerations in the design of clinical trials for cognitive aging.

Reiman EM, Brinton RD, Katz R, Petersen RC, Negash S, Mungas D, Aisen PS.

J Gerontol A Biol Sci Med Sci. 2012 Jun;67(7):766-72. doi: 10.1093/gerona/gls124. Epub 2012 May 9. Review.

13.

Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment.

Visser PJ.

J Nutr Health Aging. 2009 Apr;13(4):344-5. Review. No abstract available.

PMID:
19300874

Supplemental Content

Support Center